roxampex 10 mg/10 mg/8 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - rosuvastatinum, amlodipinum, tert-butylamini perindoprilum - apvalkotā tablete - 10 mg/10 mg/8 mg
roxampex 20 mg/5 mg/4 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - rosuvastatinum, amlodipinum, tert-butylamini perindoprilum - apvalkotā tablete - 20 mg/5 mg/4 mg
roxampex 20 mg/5 mg/8 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - rosuvastatinum, amlodipinum, tert-butylamini perindoprilum - apvalkotā tablete - 20 mg/5 mg/8 mg
roxampex 20 mg/10 mg/8 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - rosuvastatinum, amlodipinum, tert-butylamini perindoprilum - apvalkotā tablete - 20 mg/10 mg/8 mg
roxampex 10 mg/5 mg/4 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - rosuvastatinum, amlodipinum, tert-butylamini perindoprilum - apvalkotā tablete - 10 mg/5 mg/4 mg
roxampex 10 mg/5 mg/8 mg apvalkotās tabletes
krka, d.d., novo mesto, slovenia - rosuvastatinum, amlodipinum, tert-butylamini perindoprilum - apvalkotā tablete - 10 mg/5 mg/8 mg
jyseleca
gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrīts, reimatoīds - imūnsupresanti - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
orfarin 3 mg tabletes
orion corporation, finland - varfarīna nātrija sāls - tablete - 3 mg
orfarin 5 mg tabletes
orion corporation, finland - varfarīna nātrija sāls - tablete - 5 mg
begsan 25 mg/g gels
grindeks, as, latvia - ketoprofēns - gels - 25 mg/g